Caribou Biosciences (CRBU) Cash & Equivalents (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Cash & Equivalents data on file, last reported at $12.1 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 59.01% year-over-year to $12.1 million in Q1 2026; TTM through Mar 2026 was $12.1 million, a 59.01% decrease from a year earlier, with the FY2025 full-year figure at $12.4 million, down 24.14% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $12.1 million, down from $12.4 million in the prior quarter.
• Over the last five years, Cash & Equivalents for CRBU reached as high as $147.6 million in Q1 2022 and fell as low as $11.1 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $52.9 million across 5 years, with a median of $49.4 million in 2024.
• Across the five-year window, Cash & Equivalents sank 81.14% in 2022 and advanced 26.77% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $58.3 million in 2022, then retreated by 12.3% to $51.2 million in 2023, then plunged by 68.15% to $16.3 million in 2024, then decreased by 24.14% to $12.4 million in 2025, then dropped by 2.45% to $12.1 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $12.1 million in Q1 2026, $12.4 million in Q4 2025, and $11.1 million in Q3 2025.